Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8
weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide
therapy has a superior effect on insulin resistance compared to furosemide. Patients will be
subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model
(MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess
functional capacity; patient recruitment and retention success, as well as medication
adherence, will also be assessed.